Dataset Information

Determinants of survival in HER2+ metastatic esophagogastric cancer.

ABSTRACT: This cohort contains serial WES alterations from patient samples collected as part of NCT02954536, a phase 2 evaluation of chemotherapy with trastuzumab and pembrolizumab in advanced/unresectable or metastatic esophagogastric cancer.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Homo Sapiens

SUBMITTER: Memorial Sloan Kettering Cancer Center

PROVIDER: PRJEB63072 | EVA | 2023-06-12

REPOSITORIES: EVA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	s_C_001537_M001_d_vs_s_C_001537_N001_d.vcf.csi	Other
	s_C_001537_M001_d_vs_s_C_001537_N001_d.vcf.gz	Vcf
	s_C_001537_M001_d_vs_s_C_001537_N001_d.vcf.gz.csi	Vcf
	s_C_001537_P001_d_vs_s_C_001537_N002_d.vcf.csi	Other
	s_C_001537_P001_d_vs_s_C_001537_N002_d.vcf.gz	Vcf

Items per page:

1 - 5 of 192

Similar Datasets

Project description:Circulating tumor cells (CTCs) are critical in the development of distant organ tumor metastasis, and are associated with advanced cancer stage and poor patient outcome. Here, we present the first genome-wide nucleotide-level characterization of CTCs. Our single-nucleotide polymorphism (SNP) analysis in patients with melanoma involved: 1) global comparative genomic analysis of CTCs and matched regional metastases, 2) identification of key genomic aberrations in CTCs, 3) verification of these target genes in aggressive distant tumor metastases, and 4) evidence of selective expression and functional consequence of CTC-associated genes in melanomas. We report 131 aberrant loci in CTCs that are potentially pro-metastatic, and show that such expression of a 5-marker gene panel (CSMD2, CNTNAP5, FLJ14051, ADAM6, TRPM2) in melanomas confers prognostic utility. Successful treatment of melanoma requires understanding of the metastatic process and identification of patients with tumors most likely to develop aggressive metastatic disease. Melanomas are heterogeneous, and CTCs have long been recognized as vehicles for cancer spread, representing particularly aggressive tumor clones that can evolve into successful clinical metastases. Elucidation of genomic aberrations in CTCs will aid in the development of prognostic biomarkers and therapeutic strategies to target CTCs to prevent or control distant cancer spread. This study provides the first detailed genomic confirmation of the close relation between CTCs and tumor metastases, and illustrates how CTCs can be utilized as a novel approach and rational source for identification of pro-metastatic genes in cancer research. Three individual patient cohorts were utilized in the study. CNV and LOH loci were evaluated initially in metastatic melanoma patients (n=13) in a discovery cohort. SNP loci that harbored CNV/LOH in CTCs were then separately verified for: (a) presence in distant organ metastasis (AJCC Stage IV melanoma) (n=27), and (b) relevance to prognosis in regional melanoma metastasis (AJCC Stage III melanoma) (n=35). The first discovery patient cohort group was utilized for capture of CTCs, and consisted of peripheral blood mononuclear cell (PBMC) and tumor specimens from metastatic melanoma patients (n=13). CTC-related loci were verified in a second cohort of patients with Stage IV distant organ metastases (n=27), including 15 brain, 4 lung, and 8 gastrointestinal (bowel, liver) metastases. The third patient cohort consisted of early passage (<12) established melanoma cell lines derived from 35 regional melanoma metastases (Stage III) for evaluation of the prognostic utility of the CTC-associated aberrant loci.

Dataset Information

Determinants of survival in HER2+ metastatic esophagogastric cancer.

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets